v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOPICAL GLYCERYL TRINITRATE VS ORAL NIFEDIPINE IN THE TREATMENT OF IDIOPATHIC PERNIOSIS.

AUTHORS:

Kanwal Mushtaq*, Arooj Khalid*, Kiran Shehzad**

ABSTRACT:

Objective: To compare the efficacy and safety of topical glyceryl trinitrate (0.4% cream) and oral nifedipine(10mg/day) in the treatment of idiopathic perniosis. Method: The present study was conducted on 40 patients divided into two groups A(n=20) and B(n=20). Patients in group A received treatment with topical glyceryl trinitrate (0.4% cream) while patients in group B were treated with oral nifedipine (10mg/dl) for four weeks. Patients in both groups were evaluated for improvement in signs and symptoms i.e. efficacy as well as side effects, every 15 days for twelve weeks. Results: A total of 40 patients were included in the study but only 32 patients completed the study, 8 patients lost to follow up. Patients in group B have a higher rate of complete clearance of lesion. Eleven out of seventeen (64.71%) patients in group A whereas fourteen out of fifteen (93.33%) patients in group B had complete clearance of lesion in one month. Clearance of lesion was achieved earlier in group B as compared to in group A. The relapse rate during two months (off from medication) follow up in group B is low as compared to group A. The side effects are reported higher in group B as compared to group A. Conclusion: Oral nifedipine leads to earlier and complete clearance of lesion and the relapse rate is low, but side effects are reported higher in that group. Whereas 0.4% of glyceryl trinitrate cream is an effective and safe alternative treatment option for treating idiopathic perniosis. Keywords: Perniosis, chilblains, nifedipine, glyceryl trinitrate, idiopathic.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.